Latest Us Market News

Singular Health Group reported a 55% rise in net loss to $2.97 million for H1 FY2026, driven by share-based payments and strategic hires, while making significant progress in US commercial deployments and securing FDA clearance for its cloud-based 3D medical imaging platform.

Fisher & Paykel Healthcare has raised its full-year revenue and profit forecasts for FY26, buoyed by strong hospital product growth and favourable exchange rates, while navigating the complexities of a recent US Supreme Court tariff ruling.

Perenti Limited reported steady half-year revenue of $1.73 billion with a 10.9% increase in net profit, underpinned by a $300 million Dalgaranga contract and growing drilling services in the US. The company also announced an unfranked interim dividend and a CEO transition underway.

News Corp will temporarily halt conversions between its Australian and US securities registers around the March 2026 dividend record date to ensure equal treatment of shareholders.

Cobram Estate Olives reported a widened half-year loss driven by higher oil costs and operating expenses, while progressing its US growth strategy with a major California acquisition.

Li-S Energy narrows its loss to $1.21 million in H1 2026, propelled by a $7.8 million ARENA grant and key manufacturing milestones including Australia’s first lithium metal foil production line. Strategic defence and aerospace partnerships bolster its commercialisation drive.

Medical Developments International (MVP) reported an 8% revenue increase driven by strong Penthrox growth, despite a slight EBIT loss impacted by foreign exchange. The company advances pediatric approvals and targets further volume gains.

Sonic Healthcare has reported a robust half-year performance, with revenue climbing 16.6% to A$5.45 billion and net profit rising 10.9%, underpinned by organic growth and key acquisitions. The company maintains its full-year guidance amid ongoing US business rationalisation.

Zip Co has delivered a standout half-year performance with record cash earnings and upgraded FY26 guidance, driven by strong US market momentum and innovative product launches.

Cyclopharm has achieved a key milestone with Technegas approved for clinical use at the US National Institutes of Health, marking a strategic advance in its American expansion. Installation is imminent, leveraging a federal procurement framework that could broaden Technegas applications beyond pulmonary embolism.

American West Metals has appointed a top Washington DC advisory firm to deepen US government engagement for its West Desert Project, aiming to establish the first domestic indium supply chain amid critical minerals supply risks.

Pengana International Equities reported a half-year net profit of $4.6 million, down from $26.9 million last year, while announcing an increased fully franked dividend and initiating a strategic review to address shareholder concerns.